Agilent, FDA collaborate to improve testing for salmonella
Agilent Technologies Inc. announced that it has entered into a Cooperative Research and Development Agreement with the United States Food and Drug Administration to develop new tools to detect and analyze pathogens in food.
The joint R&D effort will also seek to improve DNA-based tools for confirming that seafood is correctly labeled.
The goal of the first part of the project is to develop a novel assay panel to identify subtypes of salmonella in food. When outbreaks occur, knowing the subtype can help officials quickly identify the source of the pathogen and hopefully limit the number of victims. The research will focus on using mass spectrometry-based genotyping to quickly identify salmonella subtypes.
The second part of the agreement—to be carried out in collaboration with both the FDA and the Campden BRI laboratory in the U.K.—aims to update Agilent’s lab-on-a-chip method of DNA analysis to identify fish species. Agilent’s analytical technique can identify species even after the fish has been processed, which generally removes identifying features such as the head, tail, and skin. The technology is based on the Agilent Bioanalyzer, using restriction fragment length polymorphism. The goal is to make this technology fast, inexpensive, and simple enough that many kinds of laboratories can use it on a routine basis. This type of test could detect such things as intentional mislabeling to avoid tariffs and import restrictions or economic fraud where a less expensive species of fish is sold as a more costly species.
Agilent Technologies Inc., www.agilent.com